Managers / Q2 2020 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $496M in U.S.-listed holdings across 14 positions for Q2 2020.
Its largest position, Dicerna Pharmaceuticals, represents 7.5% of the portfolio.
Compared with Q1 2020, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 47.9% · $238M
- ETP · 45.1% · $224M
- ADR · 4.0% · $20M
- Other · 2.9% · $15M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| BLUEPRINT MEDICINES CORP | NEW | +315.0K | 315.0K | +$25M | $25M |
| ARGXARGENX SE | NEW | +35.8K | 35.8K | +$8M | $8M |
| RGNXREGENXBIO INC | ADDED | +280.2K | 553.5K | +$12M | $20M |
| XBISPDR SER TR S&P BIOTECH | ADDED | +1.00M | 2.00M | +$146M | $224M |
| XENEXENON PHARMACEUTICALS INC | SOLD OUT | −1.50M | 0 | −$17M | $0 |
| MERUS N V | SOLD OUT | −770.2K | 0 | −$9M | $0 |
| QUREUNIQURE NV | ADDED | +177.6K | 679.6K | +$7M | $31M |
| ARWRARROWHEAD PHARMACEUTICALS IN | ADDED | +126.8K | 563.3K | +$12M | $24M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | DICERNA PHARMACEUTICALS INC | COM | 7.45% | $37M | 1.45M |
| 2 | ANABANAPTYSBIO INChistory → | COM | 7.17% | $36M | 1.59M |
| 3 | QUREUNIQURE NVhistory → | SHS | 6.18% | $31M | 679.6K |
| 4 | SPROSPERO THERAPEUTICS INChistory → | COM | 5.30% | $26M | 1.94M |
| 5 | BLUEPRINT MEDICINES CORP | COM | 4.95% | $25M | 315.0K |
| 6 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 4.91% | $24M | 563.3K |
| 7 | NGM BIOPHARMACEUTICALS INC | COM | 4.36% | $22M | 1.10M |
| 8 | RGNXREGENXBIO INChistory → | COM | 4.11% | $20M | 553.5K |
| 9 | PIERIS PHARMACEUTICALS INC | COM | 3.49% | $17M | 5.58M |
| 10 | PROQR THRAPEUTICS N V | SHS EURO | 2.94% | $15M | 2.40M |
| 11 | GALAPAGOS NV | SPON ADR | 1.76% | $9M | 44.2K |
| 12 | ARGXARGENX SEhistory → | SPONSORED ADR | 1.63% | $8M | 35.8K |
| 13 | MORPHOSYS AG | SPONSORED ADS | 0.61% | $3M | 95.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.